Company / Portfolio company
Prolytix.
Follow ProlytixProlytix provides regulated bioanalytical and CMC services, research reagents and custom sample collection products. VION Biosciences closed its acquisition of Prolytix in September 2026.[1]
01Deal
Deals on Carrywatch
Every deal that names Prolytix, and its role in each.
VION Biosciences (Iron Path Capital) / Prolytix
Iron Path Capital-backed VION Biosciences closed the acquisition of Prolytix from Edgewater Capital Partners on Sep 8.
Backed by Iron Path Capital.
See deal detailsDeal Web
Prolytix and 3 firms it shares a posted deal with, and the path to any other firm.
News
Loading headlines.
Sources
As of 25 Sep 2026.
- 01VION Biosciences Expands Integrated Platform Across Biopharma Services and Diagnostic Workflow Capabilities
BioSpace (VION Biosciences press release) · Researched 25 Sep 2026
Deal posts naming Prolytix:
- P01